Condition (MeSH)
Pericarditis
ClinicalTrials.gov lists 54 trials for Pericarditis or a narrower condition beneath it. Kiniksa Pharmaceuticals International, plc has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
48 of the 54 trials are tagged with Pericarditis itself; the rest are tagged with a narrower condition beneath it.
When did Pericarditis trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 8 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pericarditis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 3 |
| Phase 3 | 10 |
| Phase 4 | 3 |
| Not applicable | 3 |
| Observational | 26 |
How many Pericarditis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 10 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 6 |
| Completed | 18 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pericarditis trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kiniksa Pharmaceuticals International, plc | 3 |
| Cardiol Therapeutics Inc. | 2 |
| Kiniksa Pharmaceuticals (UK), Ltd. | 2 |
| R-Pharm International, LLC | 2 |
Which drugs are being tested for Pericarditis? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RPH - 104 | 3 |
| Cannabidiol | 2 |
| Rilonacept | 2 |
| PREDNISOLONE | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Colchicines | 7 |
| Anakinra alone (stages 2b/3) | 4 |
| KPL-387 | 2 |
| VTX2735 | 1 |
| EC Aspirin | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pericarditis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac flutter | 2 | 1 |
| Squamous cell carcinoma | 2 | 1 |
| Acute endocarditis | 1 | 1 |
| Acute myocardial infarction | 1 | 1 |
| Aortic valve disease | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pericarditis? (65)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept. | Journal of the American Heart Association | 2024 | Yes |
| Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives. | Journal of cardiovascular pharmacology | 2024 | Yes |
| Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. | Heart (British Cardiac Society) | 2023 | Yes |
| The Contemporary Role of Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging in the Diagnosis and Management of Pericardial Diseases. | The Canadian journal of cardiology | 2023 | Yes |
| Acute pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: A systemic autoinflammatory disease? A cohort study. | European journal of internal medicine | 2023 | Yes |
Showing 5 of 65 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.